New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor, which is used for non-small-cell lung cancer treatment. Erlotinib usually has a favorable safety profile however; adverse events such as interstitial lung disease (ILD) have been reported in pivotal studies. ILD usually occurs weeks to months after initiating therapy with Erlotinib. We report a case of Erlotinib induced ILD presenting within 5 days of initiating treatment with Erlotinib.
Taj
Asma
A
Department of Medicine, University of Toledo, Toledo, OH 43614, USA. asma.taj@utoledo.edu
Kanjwal
Shaffi
S
Hammersley
Jeffrey R
JR
D000368:Aged; D001706:Biopsy; D001932:Brain Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D011014:Pneumonia / Q000139:chemically induced; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors